Kera Capital Partners Inc. Buys Shares of 31,018 10x Genomics $TXG

Key Points

• Kera Capital Partners Inc. has acquired 31,018 shares of 10x Genomics, valued at approximately $359,000, during the 2nd quarter, as per their latest SEC filing.
• 10x Genomics reported earnings of $0.28 per share for the last quarter, exceeding the consensus estimate of ($0.35), along with a revenue of $172.91 million, up 12.9% year-over-year.
• Several research analysts have recently downgraded their ratings on 10x Genomics, with the average rating now at "Hold" and a consensus price target of $13.65.

Kera Capital Partners Inc. acquired a new stake in 10x Genomics (NASDAQ:TXG - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 31,018 shares of the company's stock, valued at approximately $359,000.

Several other large investors have also bought and sold shares of the business. GAMMA Investing LLC increased its stake in 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock valued at $31,000 after purchasing an additional 1,614 shares in the last quarter. Amundi increased its stake in 10x Genomics by 16,013.7% in the first quarter. Amundi now owns 320,340 shares of the company's stock valued at $2,553,000 after purchasing an additional 318,352 shares in the last quarter. Deutsche Bank AG increased its stake in 10x Genomics by 35.3% in the fourth quarter. Deutsche Bank AG now owns 10,190 shares of the company's stock valued at $146,000 after purchasing an additional 2,657 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in 10x Genomics by 235.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,103,768 shares of the company's stock valued at $62,016,000 after purchasing an additional 4,987,195 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in 10x Genomics by 163.5% in the first quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company's stock valued at $5,634,000 after purchasing an additional 400,430 shares in the last quarter. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $307,723.85. Following the completion of the sale, the chief financial officer owned 309,273 shares in the company, valued at $4,264,874.67. The trade was a 6.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Serge Saxonov sold 9,348 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the sale, the chief executive officer owned 945,892 shares of the company's stock, valued at $13,043,850.68. This trade represents a 0.98% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,149 shares of company stock worth $539,865. 9.39% of the stock is owned by insiders.

10x Genomics Trading Down 0.8%

Shares of TXG traded down $0.11 during midday trading on Friday, reaching $13.16. The stock had a trading volume of 646,049 shares, compared to its average volume of 3,293,845. The firm has a 50 day simple moving average of $13.28 and a 200-day simple moving average of $10.88. 10x Genomics has a one year low of $6.78 and a one year high of $23.53. The firm has a market cap of $1.64 billion, a PE ratio of -18.78 and a beta of 2.00.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The company had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. During the same quarter last year, the firm posted ($0.32) EPS. The company's quarterly revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, research analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TXG has been the subject of several research reports. Wall Street Zen downgraded shares of 10x Genomics from a "buy" rating to a "hold" rating in a research report on Saturday, September 13th. Morgan Stanley lowered their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Tuesday, August 12th. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research report on Saturday, September 13th. Zacks Research downgraded shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a research report on Friday, September 5th. Finally, Canaccord Genuity Group set a $16.00 price objective on shares of 10x Genomics in a research report on Monday, August 11th. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, 10x Genomics has a consensus rating of "Hold" and an average price target of $13.65.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.